Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics ( <scp>Jo‐ECAG</scp> ) ovarian study-Reference-Cited by-同舟云学术

Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics ( Jo‐ECAG ) ovarian study

Published:2022-12-19 Issue:4 Volume:11 Page:
ISSN:2324-9269
Container-title:Molecular Genetics & Genomic Medicine
language:en
Short-container-title:Molec Gen & Gen Med

Author:

Abdel‐Razeq Hikmat¹²^ORCID,Al‐Azzam Khansa¹,Elemian Shatha¹,Abu‐Fares Hala¹,Abu Sheikha Areej¹,Bani Hani Hira¹,Bater Rayan¹,Sharaf Baha’¹,Heald Brandie³,Esplin Edward D.³,Nielsen Sarah M.³,Alkyam Mais¹,Abujamous Lama⁴,Al‐Attary Areej⁵

Affiliation:

1. Department of Internal Medicine King Hussein Cancer Center Amman Jordan

2. Department of Internal Medicine the University of Jordan Amman Jordan

3. Invitae San Francisco California USA

4. Department of Cell Therapy & Applied Genomic King Hussein Cancer Center Amman Jordan

5. Department of Nursing King Hussein Cancer Center Amman Jordan

Publisher

Wiley

Subject

Genetics (clinical),Genetics,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mgg3.2125

Reference66 articles.

1. Patterns and prevalence of germline BRCA1 and BRCA2 mutations among high‐risk breast cancer patients in Jordan: A study of 500 patients;Abdel‐Razeq H.;Journal of Oncology,2020

2. Utilization and Outcomes ofBRCAGenetic Testing and Counseling in a National Commercially Insured Population

3. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review

4. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

5. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia